CClinicalTrials.gg
CompletedNCT05100563Updated May 11, 2022

Participant(s) With Autism and High Pain Tolerance Treated With High Dose Naltrexone

An observational study in Autism Spectrum Disorder, sponsored by State University of New York - Upstate Medical University. Completed at 1 site in United States. Open to participants aged 12 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by State University of New York - Upstate Medical University · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1
Ages
12 Years to 80 Years
Sex
All
01

Study summary

High dose naltrexone with response gauged by pain tolerance as measured by the cold pressor test may help treat autism.

Read the detailed description

Clinical Trial: Cause and Treatment of High Opioid Tone Autism Key Words: autism, neurobiological systems engineering, opioid tone, cold pressor time, clinical trial Abstract Introduction: Neurobiological systems engineering models are useful for treating patients. We show a model of "high opioid tone" autism and present a hypothesis about how autism is caused by administration of opioids during childbirth.

Main Symptoms: Clinical diagnosis of autism in a 25 year old man was confirmed by a Social Responsiveness Scale (SRS) self - rating of 79, severe, and a Social Communications Questionnaire (SCQ - 2) by the patient's father scoring 27. Cold pressor time is a measure of pain tolerance obtained by having the subject submerge their normal forearm in a painful ice water bath. Cold pressor time (CPT) was 190 seconds - unusually long, consonant with the high pain tolerance of autism.

Therapeutic Intervention and Outcome Measure:

Primary Outcome Measure is the Cold Pressor Time (CPT). At naltrexone 50 mg/day CPT fell to 28, repeat 39 seconds.

Secondary outcome measures are Social Responsiveness Scale (SRS) and Social Communications Questionnaire (SCQ-2). SRS fell to 54 and SCQ - 2 to 9; both non - significant for autism.

Change in relatedness was experienced ambivalently, understood as feelings never before experienced - causing pain. Non - compliance with naltrexone was followed by cutting open his palm and drinking alcoholically. Transference focused psychotherapy has helped him remain naltrexone - compliant while he works on issues of identity and relatedness.

Conclusion: The model suggests studies that could be conducted to both prevent and treat this form of autism.

02

Conditions studied

  • Autism Spectrum Disorder
03

In context

Autistic Disorder

1,344 studies on the registry are indexed under Autistic Disorder; 334 are open to participants now.

This study's enrollment of 1 is below the median of 102 across 267 observational studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

State University of New York - Upstate Medical University is the lead sponsor of 154 studies on the registry; 17 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adolescents and adults with autism spectrum disorder

Eligibility criteria

Inclusion Criteria: Diagnosis of autism -

Exclusion Criteria: Lack of ability to give informed consent

-

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1 participant (actual)
Patient registry
No

Interventions

  • Drug50 mg naltrexone

    Medication combined with twice a week psychotherapy

06

What researchers measure

Primary outcomes

  1. improvement of social responsiveness scale (SRS) and social communication questionnaire (SCQ)

    evaluation by patient at baseline and follow up of SRS and his father SCQ

    Time frame: After two weeks at optimal naltrexone dose

Secondary outcomes

  1. Cold Pressor Time

    At baseline and after optimized naltrexone dosing

    Time frame: After a week on optimized naltrexone dose with repeat two weeks later

07

Study locations

1 site
  • Upstate Medical University
    Syracuse, New York 13210, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05100563
Lead sponsor
State University of New York - Upstate Medical University
Responsible party
Sponsor
First posted
Oct 29, 2021
Start date
Oct 1, 2018
Primary completion
May 24, 2021
Completion
May 24, 2021
Last update
May 11, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion